JP7032140B2 - 嚢胞性線維症の処置のための方法及び医薬組成物 - Google Patents

嚢胞性線維症の処置のための方法及び医薬組成物 Download PDF

Info

Publication number
JP7032140B2
JP7032140B2 JP2017567701A JP2017567701A JP7032140B2 JP 7032140 B2 JP7032140 B2 JP 7032140B2 JP 2017567701 A JP2017567701 A JP 2017567701A JP 2017567701 A JP2017567701 A JP 2017567701A JP 7032140 B2 JP7032140 B2 JP 7032140B2
Authority
JP
Japan
Prior art keywords
mir
nucleic acid
ano1
inhibitor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017567701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520150A5 (https=
JP2018520150A (ja
Inventor
タバリー，オリヴィエ
ソンヌヴィル，フロランス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorbonne Universite
Original Assignee
Sorbonne Universite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorbonne Universite filed Critical Sorbonne Universite
Publication of JP2018520150A publication Critical patent/JP2018520150A/ja
Publication of JP2018520150A5 publication Critical patent/JP2018520150A5/ja
Application granted granted Critical
Publication of JP7032140B2 publication Critical patent/JP7032140B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017567701A 2015-07-03 2016-07-01 嚢胞性線維症の処置のための方法及び医薬組成物 Expired - Fee Related JP7032140B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2015/001253 2015-07-03
PCT/IB2015/001253 WO2017006145A1 (en) 2015-07-03 2015-07-03 Methods and pharmaceutical compositions for the treatment of cystic fibrosis
PCT/EP2016/065565 WO2017005646A1 (en) 2015-07-03 2016-07-01 Methods and pharmaceutical compositions for the treatment of cystic fibrosis

Publications (3)

Publication Number Publication Date
JP2018520150A JP2018520150A (ja) 2018-07-26
JP2018520150A5 JP2018520150A5 (https=) 2019-06-27
JP7032140B2 true JP7032140B2 (ja) 2022-03-08

Family

ID=54347575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567701A Expired - Fee Related JP7032140B2 (ja) 2015-07-03 2016-07-01 嚢胞性線維症の処置のための方法及び医薬組成物

Country Status (5)

Country Link
US (1) US11130950B2 (https=)
EP (1) EP3317412B1 (https=)
JP (1) JP7032140B2 (https=)
ES (1) ES2856555T3 (https=)
WO (2) WO2017006145A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019076919A1 (en) 2017-10-17 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) COMBINED TREATMENT OF CYSTIC FIBROSIS
WO2021074657A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
WO2023152369A1 (en) * 2022-02-14 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103948926A (zh) 2014-03-24 2014-07-30 江苏大学 miR-9抑制剂在制备用于抑制肿瘤生长药物中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103948926A (zh) 2014-03-24 2014-07-30 江苏大学 miR-9抑制剂在制备用于抑制肿瘤生长药物中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochimica et Biophysica Acta，2013年，Vol.1832，pp.2340-2351
Journal of Cystic Fibrosis，2015年06月，Vol.14, Suppl.1，p.S11, WS06.4

Also Published As

Publication number Publication date
WO2017005646A1 (en) 2017-01-12
ES2856555T3 (es) 2021-09-27
US11130950B2 (en) 2021-09-28
EP3317412B1 (en) 2020-12-02
WO2017005646A8 (en) 2017-10-19
WO2017006145A1 (en) 2017-01-12
EP3317412A1 (en) 2018-05-09
JP2018520150A (ja) 2018-07-26
US20200040332A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
JP6919098B2 (ja) 筋強直性ジストロフィー１型に対するマイクロｒｎａの変調及びそのためのマイクロｒｎａのアンタゴニスト
WO2023051822A1 (zh) 用于治疗与pcsk9相关疾病的靶向寡核苷酸
CN107636003A (zh) miR‑92抑制剂及其用途
JP7032140B2 (ja) 嚢胞性線維症の処置のための方法及び医薬組成物
CN111566212A (zh) miRNA分子，等同物，安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生
AU2009289239B2 (en) Treatment of scleroderma
JP2024532019A (ja) アルファ－１アンチトリプシン発現を阻害するための組成物及び方法
US20200123549A1 (en) Enhanced organogenesis through manipulation of lin28/let-7/dis3l2
EP4421173A1 (en) Use of micrornas in the treatment of lung diseases
EP4616905A1 (en) Use of inhibitors of micrornas in the treatment of lung diseases
WO2023152369A1 (en) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
US20220275375A1 (en) Compositions and methods for the treatment of hypercholesterolemia
US20170067061A1 (en) Microrna treatment of fibrosis
KR20200055723A (ko) 인슐린 저항성 검출 및 치료용 조성물 및 방법
US20230279393A1 (en) Treatment of Airway Conditions by Modulation of MiR200 Family MicroRNAs
WO2026028149A1 (en) Guide rnas for editing serpina1, and compositions and methods relating thereto
EP4642913A2 (en) Splice-switching oligonucleotides for treating syngap1-associated disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200902

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20201002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210512

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210512

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210525

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210806

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220224

R150 Certificate of patent or registration of utility model

Ref document number: 7032140

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees